Sudarshan Pharma Soars 10 Percent as Q3FY26 Sales and Profits Rise

Mumbai (Maharashtra) [India], February 05: Sudarshan Pharma Industries Ltd. jumped to a 10 per cent upper circuit on Thursday, closing at Rs 23.10 per share from the prior close of Rs 21. The stock, which has a 52‑week high of Rs 38.71 and a 52‑week low of Rs 18.50, gained momentum after the company reported robust quarterly and nine‑month results alongside a strategic international move to strengthen its European presence.

In Q3FY26, Sudarshan Pharma posted net sales of Rs 168.01 crore, up 16 per cent year‑on‑year from Q3FY25, and delivered a notable 51 per cent jump in net profit to Rs 4.36 crore. The company's performance over the first nine months of FY26 was even stronger, with net sales rising 40 per cent to Rs 482.14 crore and net profit increasing 67 per cent to Rs 12.58 crore versus 9MFY25. Reflecting steady longer‑term growth, Sudarshan Pharma's FY25 annual results showed net sales of Rs 505 crore, a 9 per cent increase over FY24, and net profit of Rs 16 crore, up 45 per cent year‑on‑year.

Bolstering its growth strategy, Sudarshan Pharma has incorporated a wholly‑owned subsidiary, Sudarshan Pharma Company Poland Limited Liability, in Warsaw. Approved by the board in February 2025 with an initial investment of PLN 5,000 for a 100 per cent stake, the new entity is intended to expand the company's European customer base. The Warsaw subsidiary will focus on the manufacture of chemicals, fertilisers and plastics, and the wholesale of pharmaceutical products, positioning Sudarshan Pharma to capture new industrial opportunities across chemical, agrochemical and pharmaceutical value chains in Europe.

Established in 2008 and headquartered in Mumbai, Sudarshan Pharma Industries Ltd. specialises in the production of Active Pharmaceutical Ingredients (APIs), pharmaceutical items, and the trading of chemicals and solvents. The company offers a broad portfolio ranging from bulk chemicals and intermediates to finished formulations, with multiple products registered under its “R” trademark and consumer brands such as Love Birds and Metfocal. Sudarshan Pharma serves both domestic and international markets, exporting to regions including Southeast Asia, the Middle East and North Africa, and now signaling a strategic push into Europe to complement its existing global footprint.

Disclaimer: This article is for informational purposes only and does not constitute financial advice.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor